AIM AIM ImmunoTech Inc. Total Debt to Capital

This chart of current AIM (AIM) quotes demonstrates a total debt-to-equity ratio of 0.50. The firm's financial stability is declining due to the slow market rollout of Ampligen, which undermines profitability despite existing patents. Pipeline risks are being minimized through the adaptation of immunomodulators to combat oncology and viruses. High product quality is guaranteed by the implementation of automated interferon synthesis systems.

This metric measures the proportion of borrowed funds within the balance sheet structure, determining the business's level of dependence on external financing and its vulnerability to credit shocks. The diversification of Ampligen clinical trials reduces operational risks for AIM ImmunoTech (AIM), meaning an analysis of the debt-to-equity ratio allows investors to assess the company's financial stability while executing its long-term strategy for immunomodulator development.